Merck’s Recarbrio (imipenem/cilastatin/relebactam) Receives the US FDA’s Approval for Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections

 Merck’s Recarbrio (imipenem/cilastatin/relebactam) Receives the US FDA’s Approval for Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections

Merck’s Recarbrio (imipenem/cilastatin/relebactam) Receives the US FDA’s Approval for Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections

Shots:

  • The US FDA approval is based on clinical safety and efficacy data of Recarbrio (injection, 1.25gm) approved for cUTI including pyelonephritis, caused by certain Gram-negative microorganism and also indicated for patients with cIAI aged 18yrs.+ who have limited or no alternative treatment options
  • The US FDA reviewed its NDA under Qualified Infectious Disease Product (QIDP) designation for cUTI and cIAI and has received PR designation
  • Recarbrio is a triple combination therapy comprising of Imipenem (penem antibiotic), cilastatin sodium (renal dehydropeptidase inhibitor) and relebactum (beta-lactamase inhibitor) and is expected to be available in the US in H2’19

Click here to read full press release/ article | Ref: Merck | Image: The Times Herald

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post